Owners, management and financials
CVR: 18652439
Secondary names: JACOBSEN PHARMA A/S, JACOBSEN PHARMA & MEDICO A/S, JACOBSEN REGULATORY CONSULTING A/S
Previous names: SLP NR. 11.026 A/S, JACOBSEN PHARMA CONSULTANCY A/S
DKK 17,235,093
Gross profit
Net result: DKK -1,712,095
Pharmalex Nordic ApS (100%)
CVR · view owners
Åsa Pihlblad
Board: Christopher Gauglitz (chair) and 2 members
CVR · view management
Active
Founded 1 July 1995
CVR · view overview
16 employees
CVR · 2018
Director role ended: Torben Thers Nørgaard
CVR · 01/10/2024
View the full event history
PharmaLex Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 1995. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named JACOBSEN PHARMA CONSULTANCY A/S and SLP NR. 11.026 A/S. The management consists of Åsa Pihlblad. The board consists of Christopher Gauglitz (chair), Carlos Antonio Santaflorentina Juanino and Åsa Pihlblad. The company is owned by Pharmalex Nordic ApS. The company has 16 employees (2018). In 2025, the company reported a gross profit of DKK 17,235,093 and a net result of DKK -1,712,095 compared with DKK 1,745,746 the year before. Equity in the 2025 report amounted to DKK 2,761,242.
Source: annual report 2025, Danish Business Authority
PharmaLex Denmark A/S is currently facing financial challenges, as evidenced by a significant decline in profitability, reporting a loss of 1,712,095 DKK in 2025 after generating a profit of 1,745,746 DKK in 2024. Gross profit has decreased from 29,956,915 DKK in 2022 to 17,235,093 DKK in 2025, indicating a downward trend. Equity has also dropped from 6,583,431 DKK in 2022 to 2,761,242 DKK in 2025, raising concerns about the company's financial stability. Despite its established presence in the management consulting industry since 1995, the declining profit margins and equity position suggest a need for strategic reassessment to improve its financial health.
AI-generated summary · Generated 15/08/2026
Selskabets formål er konsulentvirksomhed, farmaceutisk virksomhed, handel, produktion samt landbrugsproduktion
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/10/2024 – 30/09/2025 | 17.2 mio. | -1.7 mio. | 18.3 mio. | 2.8 mio. | 18 | |
| 202401/10/2023 – 30/09/2024 | 26 mio. | 1.7 mio. | 12.5 mio. | 6 mio. | 25 | |
| 202201/01/2022 – 31/12/2022 | 30 mio. | 5.8 mio. | 12.9 mio. | 6.6 mio. | 29 | |
| 202101/01/2021 – 31/12/2021 | 22.7 mio. | 2.6 mio. | 11.3 mio. | 3.9 mio. | 25 | |
| 202001/01/2020 – 31/12/2020 | 21.5 mio. | 4.3 mio. | 14.3 mio. | 6.2 mio. | 23 | |
| 201901/01/2019 – 31/12/2019 | 17 mio. | 3.7 mio. | 12.4 mio. | 6 mio. | 18 | |
| 201801/01/2018 – 31/12/2018 | 13.4 mio. | 2.9 mio. | 7.1 mio. | 4.1 mio. | 15 | |
| 201701/01/2017 – 31/12/2017 | 14.5 mio. | -1.6 mio. | 5.7 mio. | 1.2 mio. | 21 | |
| 201601/01/2016 – 31/12/2016 | 22.4 mio. | 5.3 mio. | 10.4 mio. | 6.6 mio. | 30 | |
| 201501/01/2015 – 31/12/2015 | 17.6 mio. | 321 t. | 11.8 mio. | 4.9 mio. | - | |
| 201401/01/2014 – 31/12/2014 | 15.4 mio. | 2.2 mio. | 16.2 mio. | 6.8 mio. | - | |
| 201301/01/2013 – 31/12/2013 | 12.7 mio. | 2.5 mio. | 14.1 mio. | 6.9 mio. | - | |
| 201201/01/2012 – 31/12/2012 | 9.9 mio. | 2.3 mio. | 15.8 mio. | 7.2 mio. | - |
Compared to 11.553 companies in Virksomhedsrådgivning og anden ledelsesrådgivning
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of PharmaLex Denmark A/S is 18652439.
PharmaLex Denmark A/S is owned by Pharmalex Nordic ApS.
The management of PharmaLex Denmark A/S consists of Åsa Pihlblad.
The board of PharmaLex Denmark A/S consists of Christopher Gauglitz, Carlos Antonio Santaflorentina Juanino and Åsa Pihlblad, with Christopher Gauglitz as chair.
In 2025, PharmaLex Denmark A/S reported a gross profit of DKK 17,235,093.
PharmaLex Denmark A/S had 16 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new phone: 74441936, new email: [email protected] (May 13, 2026).
As of May 4, 2026, Carlos Antonio Santaflorentina Juanino has joined the board of directors of PharmaLex Denmark A/S.
As of May 4, 2026, Eva Edil has left the board of directors of PharmaLex Denmark A/S.
PharmaLex Denmark A/S has published its annual report for 2025. Gross profit came to DKK 17,235,093, and the net result was DKK -1,712,095.
Address changed to Lyngby Hovedgade 10C 10, 2800 Kongens Lyngby (February 3, 2026).
Contact info changed: new phone: 74441936, new email: [email protected] (February 3, 2026).
PharmaLex Denmark A/S has published its annual report for 2024. Gross profit came to DKK 26,015,255, and the net result was DKK 1,745,746.
As of October 31, 2024, Eva Edil has joined the board of directors of PharmaLex Denmark A/S.
As of October 31, 2024, Laurent Maurice Robert Couston has left the board of directors of PharmaLex Denmark A/S.
As of October 1, 2024, Åsa Pihlblad has joined the board of directors of PharmaLex Denmark A/S.
As of October 1, 2024, Torben Thers Nørgaard has left the board of directors of PharmaLex Denmark A/S.
As of October 1, 2024, Åsa Pihlblad is registered as adm. dir. of PharmaLex Denmark A/S.
As of October 1, 2024, Torben Thers Nørgaard has stepped down as adm. dir. of PharmaLex Denmark A/S.
PharmaLex Denmark A/S has published its interim report for the period January 1, 2023 – September 30, 2023.
As of May 25, 2023, Laurent Maurice Robert Couston has joined the board of directors of PharmaLex Denmark A/S.
As of May 25, 2023, Christopher Gauglitz has joined the board of directors of PharmaLex Denmark A/S.
As of May 25, 2023, Eva Edil has left the board of directors of PharmaLex Denmark A/S.
As of May 25, 2023, Dr. Thomas Stefan Dobmeyer has left the board of directors of PharmaLex Denmark A/S.
PharmaLex Denmark A/S has published its annual report for 2022. Gross profit came to DKK 29,956,915, and the net result was DKK 5,780,476.
PharmaLex Denmark A/S has published its annual report for 2021. Gross profit came to DKK 22,717,794, and the net result was DKK 2,633,665.
PharmaLex Denmark A/S has published its annual report for 2020. Gross profit came to DKK 21,537,258, and the net result was DKK 4,266,469.
PharmaLex Denmark A/S has published its annual report for 2019. Gross profit came to DKK 17,037,411, and the net result was DKK 3,695,302.
PharmaLex Denmark A/S has published its annual report for 2018. Gross profit came to DKK 13,391,778, and the net result was DKK 2,874,449.
PharmaLex Denmark A/S has published its annual report for 2017. Gross profit came to DKK 14,539,514, and the net result was DKK -1,627,342.
As of March 20, 2018, Eva Edil has joined the board of directors of PharmaLex Denmark A/S.
As of March 20, 2018, Dr. Thomas Stefan Dobmeyer has joined the board of directors of PharmaLex Denmark A/S.
As of March 20, 2018, Anette Langgaard Jacobsen has left the board of directors of PharmaLex Denmark A/S.
As of March 19, 2018, Dr. Thomas Stefan Dobmeyer has left the board of directors of PharmaLex Denmark A/S.
As of January 17, 2018, Dr. Thomas Stefan Dobmeyer has joined the board of directors of PharmaLex Denmark A/S.
As of January 17, 2018, Solveig Blomvik has left the board of directors of PharmaLex Denmark A/S.
On November 6, 2017, the company changed its name from JACOBSEN PHARMA CONSULTANCY A/S to PharmaLex Denmark A/S.
As of November 6, 2017, Pharmalex Nordic ApS is registered as an owner of PharmaLex Denmark A/S with an ownership share of 100%.
PharmaLex Denmark A/S has published its annual report for 2016. Gross profit came to DKK 22,356,214, and the net result was DKK 5,319,161.
As of January 1, 2017, Anette Langgaard Jacobsen has joined the board of directors of PharmaLex Denmark A/S.
As of January 1, 2017, Solveig Blomvik has joined the board of directors of PharmaLex Denmark A/S.
As of January 1, 2017, Torben Thers Nørgaard has joined the board of directors of PharmaLex Denmark A/S.
As of January 1, 2017, Raphael Troost has left the board of directors of PharmaLex Denmark A/S.
As of January 1, 2017, Caren Ingrid Martini has left the board of directors of PharmaLex Denmark A/S.
As of January 1, 2017, Torben Thers Nørgaard is registered as adm. dir. of PharmaLex Denmark A/S.
As of January 1, 2017, Anette Langgaard Jacobsen has stepped down as director of PharmaLex Denmark A/S.
As of December 31, 2016, Anette Langgaard Jacobsen has left the board of directors of PharmaLex Denmark A/S.
As of October 20, 2016, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of PharmaLex Denmark A/S.
As of October 20, 2016, SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of PharmaLex Denmark A/S.
As of July 5, 2016, Raphael Troost has joined the board of directors of PharmaLex Denmark A/S.
As of July 5, 2016, Caren Ingrid Martini has joined the board of directors of PharmaLex Denmark A/S.
As of July 5, 2016, Henrik Kagenow has left the board of directors of PharmaLex Denmark A/S.
As of July 5, 2016, Jakob Langgaard Wisnewski has left the board of directors of PharmaLex Denmark A/S.
PharmaLex Denmark A/S has published its annual report for 2015. Gross profit came to DKK 17,574,734, and the net result was DKK 320,835.
As of March 16, 2016, Henrik Kagenow has joined the board of directors of PharmaLex Denmark A/S.
As of March 16, 2016, Anette Langgaard Jacobsen has joined the board of directors of PharmaLex Denmark A/S.
As of March 16, 2016, Elsebeth Budolfsen has left the board of directors of PharmaLex Denmark A/S.
As of March 15, 2016, Henrik Kagenow has left the board of directors of PharmaLex Denmark A/S.
PharmaLex Denmark A/S has published its annual report for 2014. Gross profit came to DKK 15,365,167, and the net result was DKK 2,238,188.
PharmaLex Denmark A/S has published its annual report for 2013. Gross profit came to DKK 12,677,713, and the net result was DKK 2,468,065.
PharmaLex Denmark A/S has published its annual report for 2012. Gross profit came to DKK 9,854,675, and the net result was DKK 2,321,466.
As of June 26, 2012, Henrik Kagenow has joined the board of directors of PharmaLex Denmark A/S.
As of June 26, 2012, Niels Bjerregaard has left the board of directors of PharmaLex Denmark A/S.
As of October 22, 2010, SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of PharmaLex Denmark A/S.
As of October 22, 2010, SØNDERJYLLANDS REVISION SØNDERBORG, STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of PharmaLex Denmark A/S.
As of March 25, 2010, Niels Bjerregaard has joined the board of directors of PharmaLex Denmark A/S.
As of March 25, 2010, Per Egebæk Have has left the board of directors of PharmaLex Denmark A/S.
As of June 16, 2008, SØNDERJYLLANDS REVISION SØNDERBORG, STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of PharmaLex Denmark A/S.
As of June 16, 2008, Erik Peter Andersen has stepped down as auditor of PharmaLex Denmark A/S.
As of June 16, 2008, Jakob Langgaard Wisnewski has joined the board of directors of PharmaLex Denmark A/S.
As of June 16, 2008, Laurits Thorvald Larsen has left the board of directors of PharmaLex Denmark A/S.
As of June 13, 2007, Per Egebæk Have has joined the board of directors of PharmaLex Denmark A/S.
As of June 13, 2007, Finn Wisnewski has left the board of directors of PharmaLex Denmark A/S.
As of June 10, 2006, Elsebeth Budolfsen has joined the board of directors of PharmaLex Denmark A/S.
As of June 10, 2006, Laurits Thorvald Larsen has joined the board of directors of PharmaLex Denmark A/S.
As of June 10, 2006, Anette Langgaard Jacobsen has left the board of directors of PharmaLex Denmark A/S.
As of June 10, 2006, Michael Clemmensen has left the board of directors of PharmaLex Denmark A/S.
As of July 30, 2002, Erik Peter Andersen has been appointed auditor of PharmaLex Denmark A/S.
As of July 30, 2002, Leif Ove Rasmussen has stepped down as auditor of PharmaLex Denmark A/S.
On September 6, 1995, the company changed its name from SLP NR. 11.026 A/S to JACOBSEN PHARMA CONSULTANCY A/S.
As of August 31, 1995, Leif Ove Rasmussen has been appointed auditor of PharmaLex Denmark A/S.
As of August 31, 1995, Harry Aamann has stepped down as auditor of PharmaLex Denmark A/S.
As of August 31, 1995, Finn Wisnewski has joined the board of directors of PharmaLex Denmark A/S.
As of August 31, 1995, Anette Langgaard Jacobsen has joined the board of directors of PharmaLex Denmark A/S.
As of August 31, 1995, Michael Clemmensen has joined the board of directors of PharmaLex Denmark A/S.
As of August 31, 1995, Preben Bang Henriksen has left the board of directors of PharmaLex Denmark A/S.
As of August 31, 1995, Mogens Gaardboe Bertelsen has left the board of directors of PharmaLex Denmark A/S.
As of August 31, 1995, Lone Mai Henriksen has left the board of directors of PharmaLex Denmark A/S.
As of August 31, 1995, Anette Langgaard Jacobsen is registered as director of PharmaLex Denmark A/S.
As of August 31, 1995, Preben Bang Henriksen has stepped down as director of PharmaLex Denmark A/S.
As of July 1, 1995, Harry Aamann has been appointed auditor of PharmaLex Denmark A/S.
As of July 1, 1995, Preben Bang Henriksen has joined the board of directors of PharmaLex Denmark A/S.
As of July 1, 1995, Mogens Gaardboe Bertelsen has joined the board of directors of PharmaLex Denmark A/S.
As of July 1, 1995, Lone Mai Henriksen has joined the board of directors of PharmaLex Denmark A/S.
As of July 1, 1995, Preben Bang Henriksen is registered as director of PharmaLex Denmark A/S.
PharmaLex Denmark A/S was founded on July 1, 1995.
Companies in the same industry and area
CVR 36151609
CVR 45914682
CVR 25998189
CVR 25813294
CVR 43237179
